Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate ...
The stock is trading at $5.69, up 2.92, gaining 105.40% on volume of over 61 Million shares. The stock had a morning high of ...
Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
A recent Northwestern Medicine study has identified novel neural circuits modulated by the diabetes and obesity-management ...
Sequels are opportunities to either build upon a predecessor and push boundaries, or refine what was already great and deliver that again with a stronger focus. With Ghost of Yotei, developer Sucker ...
Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback